Generali Investments Management’s Neurocrine Biosciences NBIX Stock Holding History

Generali Investments Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.79M	Buy	10,644 +1,762	+20%	+$261K	0.39%	55
2026 Q1	$1.17M	Sell	8,882 -25	-0.3%	-$3.32K	0.27%	73
2025 Q4	$1.26M	Buy	8,907 +3,949	+80%	+$572K	0.25%	67
2025 Q3	$696K	Buy	4,958 +2,415	+95%	+$327K	0.15%	96
2025 Q2	$319K	Buy	+2,543	New	+$292K	0.07%	114

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Generali Investments Management's NBIX Position: Q2 2026 in Review

Generali Investments Management increased its Neurocrine Biosciences (NBIX) stake by 20% in Q2 2026, buying an estimated $261K and bringing the position to 10,644 shares worth $1.79M. The position accounts for 0.39% of the portfolio, ranked #55.

Generali Investments Management first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Generali Investments Management held 10,644 shares of Neurocrine Biosciences worth $1.79M as of Q2 2026.
Generali Investments Management bought 1,762 Neurocrine Biosciences shares in Q2 2026, an estimated $261K.
Neurocrine Biosciences made up 0.39% of Generali Investments Management's portfolio in Q2 2026, its #55 holding.
Generali Investments Management first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Generali Investments Management's 13F filing for Q2 2026, filed 10 Jul 2026.